OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentAetnaPolicy 0783

In Vivo Analysis of Gastro-Intestinal and Urothelial Lesions

Customize your policy alerts

Sign up for Aetna Policy 0783 alerts

Get alerted when Policy 0783 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This policy governs coverage determinations for in vivo optical/ endomicroscopy and related technologies used to analyze gastro-intestinal and urothelial lesions, affecting providers submitting claims to Aetna for these procedures.

Policy Summary

PayerAetna

PolicyIn Vivo Analysis of Gastro-Intestinal and Urothelial Lesions

Policy CodePolicy 0783

Change TypeNo material change

Effective DateApr 24, 2009

Last ReviewOct 17, 2023

Next Review DateAug 22, 2024

Key ActionVerify prior authorization requirements and document indication, imaging findings, and correlation with histopathology when submitting claims for in vivo optical/endomicroscopy procedures.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

29+listed experimental/investigational indications or uses

1FDA PMA device discussed

90%+ NPVmeets high-confidence NPV in subgroup

10/17/2023policy last reviewed

Coverage Criteria — Optical / In‑Vivo Analysis

Experimental and Investigational

Aetna considers the following experimental and investigational (not established/effective):

Experimental/Investigational Uses

Technologies: Chromoendoscopy; confocal laser (fluorescent) endomicroscopy including Cellvizio probe‑based CLE; endocytoscopy; EVIS EXERA 160A System; fiberoptic analysis; multi‑band imaging; narrow‑band imaging optical chromocolonoscopy; Optical Biopsy System; Pentax Confocal Laser System; WavSTAT™ Optical Biopsy System; and elastic‑scattering spectroscopy.
(chunk 4)
Procedural combinations: ERCP with optical endomicroscopy for evaluation of biliary lesions (including strictures).
(chunk 4)
Clinical indications for CLE and related modalities: Use of CLE (including probe‑based Cellvizio) for assessment of safe surgical margins during laryngectomy; bronchoscopic evaluation of broncho‑alveolar lavage components; confirmation of low‑grade dysplasia and surveillance of Barrett’s esophagus; detection of colorectal mucosal microinflammation in irritable bowel syndrome; detection of neoplasia in PSC‑associated biliary strictures; diagnosis and histologic grading of bladder cancer; diagnosis and monitoring of urogenital schistosomiasis; diagnosis and staging of lung cancer; diagnosis of acute cellular rejection in lung transplant recipients; diagnosis of clinical complete response after chemoradiation for rectal cancer; diagnosis of early‑stage gastric or ovarian cancer; diagnosis of functional dyspepsia; diagnosis of head and neck squamous cell carcinoma (laryngeal/pharyngeal SCC); diagnosis of indeterminate biliary strictures and pancreatic lesions; diagnosis of liver cancer; diagnosis of prostate cancer; diagnosis of vocal cord lesions; evaluation and prediction of IBD course and therapeutic response; differentiation of benign and malignant gallbladder polyps; differentiation of colorectal polyps during routine colonoscopy; differentiation of parenchymal lung diseases; evaluation of depth of invasion in colorectal lesions; evaluation of epithelial barrier function/GERD; intra‑operative use for glioblastoma or other CNS tumors; intra‑operative use during surgery for Hirschsprung's disease; and management of upper tract urothelial carcinoma.

Coding — CPT / HCPCS / ICD-10 / Regulatory Identifiers

CPT codes noted in policyCPT

0397T	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure).
43206	Esophagoscopy, flexible, transoral; with optical endomicroscopy [confocal laser endomicroscopy].
43252	Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy [confocal laser endomicroscopy].

Other related CPT codesCPT

45378

Colonoscopy, flexible; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure).

HCPCS screening codesHCPCS

G0105	Colorectal cancer screening; colonoscopy on individual at high risk.
G0121	Colorectal cancer screening; colonoscopy on individual not meeting the criteria for high risk.

ICD-10 codes referenced as not covered or discussedICD-10

B65.0	Schistosomiasis due to Schistosoma haematobium [urinary schistosomiasis].
C15.3 - C26.9	Malignant neoplasms of digestive organs [early stage gastric cancer].
C34.00 – C34.92	Malignant neoplasm of bronchus and lung.
C67.0 - C67.9	Malignant neoplasm of bladder [urothelial carcinoma].
K21.00 – K21.9	Gastro-esophageal reflux disease.
K50.00 - K50.919	Crohn's disease [regional enteritis].
K51.00 - K51.919	Ulcerative colitis.
K63.5	Polyp of colon.
Z12.11	Encounter for screening for malignant neoplasm of colon.
Z86.010	Personal history of colonic polyps.

No codes listed in this excerptmixed

No codes listed

Regulatory device identifier citedFDA

K051645

FDA 510(k) Evis Exera 160A System (510(k) No. K051645)

Provider Actions — Prior Authorization, Documentation, and Denial Risk

Prior Authorization

Potential prior authorization for listed procedure codes

Certain CPT/HCPCS codes related to in‑vivo optical diagnostic procedures (see CPT/HCPCS section of this policy) may be subject to prior authorization. Providers should verify prior authorization requirements with the member’s plan before scheduling or billing these procedures.

Check plan-specific code lists and bulletin for any required prior authorization.
Examples of relevant codes include endoscopic procedures with optical endomicroscopy (e.g., 0397T) and CPT codes listed in the CPT/HCPCS section.

Prior Authorization

Prior review advised before substituting pathology

Advanced optical imaging modalities are investigational for many indications and should not be used to routinely substitute for histopathology without prior review. When clinicians propose management that bypasses standard tissue diagnosis based on in‑vivo imaging alone, prior review is advised.

Do not forego histopathology solely on the basis of optical diagnosis unless an authorized prior review process has approved that approach.

Background — Clinical Context and Evidence

Colorectal cancer is a common condition for which early lesions can be treated endoscopically, but polypectomy carries procedural risks (for example, hemorrhage and perforation). New optical imaging approaches (narrow‑band imaging, confocal endomicroscopy, optical biopsy systems and related technologies) aim to improve real‑time detection and characterization of lesions to reduce unnecessary polypectomies and to guide management; however, the evidence base largely consists of small studies, pilot trials and a limited number of randomized trials with mixed results and concerns about generalizability and standardization.

Definitions and Device Descriptions

inv-78: Optical Biopsy System — laser-based device adjunct for lower GI endoscopy

DeviceOptical Biopsy System (SpectraScience) — laser‑based fiber‑optic device analyzing tissue autofluorescence as an adjunct to lower GI endoscopy

FDA statusPremarket Approval (PMA No. P990050) for adjunctive evaluation of polyps <1 cm that the physician has not already elected to remove

Intended useUsed only to help decide whether small (<1 cm) polyps should be removed; adjunct to visual assessment

Study basis for approvalPMA based on an unpublished prospective, nonrandomized phase II study (n=101) submitted by manufacturer

Performance in studyCombined physician assessment + device: sensitivity 96.3% and specificity 33%; physician assessment alone: sensitivity 82.7% and specificity 50%

Policy Dates and Administrative Info

2009-04-24policy_effective

Policy effective date published for Aetna's clinical policy bulletin on in vivo analysis of gastrointestinal and urothelial lesions.

2000-11-14device_PMA_reference

FDA PMA for the Optical Biopsy System (PMA No. P990050) is cited in the policy references.

2005-10-13device_510k_reference

FDA 510(k) for the Evis Exera 160A System (K051645) is cited in the policy references.

Policy Summary

PayerAetna

PolicyIn Vivo Analysis of Gastro-Intestinal and Urothelial Lesions

Policy CodePolicy 0783

Change TypeNo material change

Effective DateApr 24, 2009

Last ReviewOct 17, 2023

Next Review DateAug 22, 2024

Key ActionVerify prior authorization requirements and document indication, imaging findings, and correlation with histopathology when submitting claims for in vivo optical/endomicroscopy procedures.

SourceLink

On This Page

Contexts where optical diagnosis may approach histopathology

Evidence-based performance thresholds and application contexts reported in the literature

ASGE/PIVI performance thresholds met in select contexts: High‑confidence narrow‑band imaging (NBI) predictions for diminutive (≤5 mm) recto‑sigmoid polyps achieved sensitivity ~90%, specificity ~88%, and negative predictive value (NPV) ≈92% in multicenter study (Repici et al.), meeting ASGE PIVI thresholds for some 'diagnose‑and‑leave' or surveillance interval decisions when made with high confidence and appropriate training.ASGE PIVI ≥90% agreement and ≥90% NPV in high‑confidence subgroup

(chunk 37)

High diagnostic accuracy in pooled analyses: Meta‑analyses/meta‑reviews report high pooled sensitivity and specificity for digital chromoendoscopy (sensitivity ~92.2%, specificity ~84.0%) and for endomicroscopy in some analyses (pooled sensitivity up to ~93.6% and specificity ~92.5%), indicating that certain optical technologies can approximate histopathology in research/experienced‑center settings.none

(chunks 54, 55)

Importance of high confidence and training: Studies repeatedly show that high‑confidence predictions and endoscopist qualification/training were required to reach these performance thresholds; results from specialized centers may not generalize to routine community practice.endoscopist training/qualification documented

(chunks 37, 54)

Limitations for routine adenoma detection

Evidence where routine use for adenoma detection is not supported

NBI does not consistently improve adenoma detection: Multiple randomized trials, Cochrane review and meta‑analyses found no significant improvement in adenoma or polyp detection rates with NBI versus high‑definition white‑light colonoscopy; overall evidence does not support routine adoption of NBI to increase adenoma detection in average practice.none

(chunks 26, 27, 29)

Community performance may be inferior to reference centers: Implementation studies showed lower real‑world diagnostic accuracy (example: routine screening practice accuracy ~76.6% with image‑based surveillance recommendations correct in ~69.5%), indicating routine community use may not meet thresholds needed to omit histopathology.none

(chunk 44)

When optical diagnosis may be acceptable

Covered use considerations when ALL of the following apply

Lesion and prediction characteristics: Optical diagnosis may be acceptable when the assessment is limited to diminutive recto‑sigmoid polyps (≤5 mm) and the endoscopist documents a high‑confidence prediction that meets ASGE/PIVI thresholds (≥90% agreement for surveillance interval and ≥90% NPV).NPV ≥90% and ≥90% agreement for surveillance interval in high‑confidence subgroup

(chunk 37)

Operator qualification and validated protocols: The endoscopist has completed validated training/qualification for the specific optical modality and criteria used, and documentation records confidence level and method used.documented endoscopist training/qualification and high‑confidence designation

(chunks 31, 37)

Use limited to settings matching evidence base: Application is in a setting and patient population similar to those in the supporting studies (experienced centers, protocolized image classification) and not generalized immediately to routine community practice without monitoring or additional validation.setting and patient selection align with supportive studies

(chunks 54, 31)

When optical diagnosis is insufficient

Not covered or not recommended when ANY of the following apply

Routine replacement of histopathology or surveillance without validation: Using in‑vivo optical classification as a routine substitute for histopathologic assessment or to determine surveillance intervals in community practice when accuracy has not been demonstrated locally is not recommended.accuracy below guideline thresholds or lack of local validation

(chunks 44, 55)

Unproven substitution after implementation: Implementing chromoendoscopy or other optical methods in a surveillance program without evidence of improved dysplasia detection compared with white‑light endoscopy with targeted/random biopsies is not supported for routine practice.no demonstrated increase in dysplasia detection post‑implementation

(chunk 47)

Evidence-based conclusions and coverage implications

Summary of findings and implications for coverage

Evidence synthesis: Meta‑analyses and systematic reviews show promising diagnostic performance for specific optical technologies (digital chromoendoscopy pooled sensitivity ≈92% and specificity ≈84%; CLE pooled sensitivities ~91–94% with variable specificity), but studies are heterogeneous, often small, and subject to publication bias and declining NPV over time.

(chunks 54, 55, 56)

Limitations and operational concerns: Important limitations include limited generalizability from specialized centers to community practice, learning‑curve effects, limited penetration depth (eg, CLE ~55–65 μm), small field of view, image‑selection bias, and non‑negligible procedure‑specific adverse events (e.g., pancreatitis with nCLE).

(chunks 66, 125, 90)

Coverage implications: Given the mixed and preliminary evidence, many in‑vivo optical modalities and indications remain investigational; selective, evidence‑aligned use (eg, high‑confidence digital chromoendoscopy for diminutive recto‑sigmoid polyps, or nCLE for selected indeterminate pancreatic cysts in experienced centers) may be considered on a case‑by‑case basis with prior review and appropriate documentation.case‑by‑case prior review and supporting documentation

(chunks 55, 85, 90)

Evidence-supported use cases

Evidence summaries and contexts where CLE / nCLE demonstrated diagnostic utility:

Bladder cancer grading (pCLE): CLE has shown reasonable concordance with histopathology for grading bladder tumors in single‑center studies and pooled analyses report pooled sensitivity ~0.90 and AUC ~0.91, though limitations include small sample sizes and difficulty with flat lesions and CIS.

(chunks 72, 74)

Pancreatic cysts (nCLE): nCLE in multi‑center and single‑center studies demonstrated high diagnostic performance for classifying pancreatic cystic lesions (conclusive rate ~91%; sensitivity/specificity/accuracy for mucinous PCLs reported as high as 98%/94%/97% in a prospective study), with pooled diagnostic accuracy ~83% and AE (post‑procedure pancreatitis) rates ~2–3.5%.

(chunks 85, 86, 90)

Biliary strictures (pCLE): Probe‑based CLE during ERCP increased sensitivity for indeterminate biliary strictures compared with tissue sampling alone in multicenter prospective data (pCLE+ERCP sensitivity ~89% vs tissue sampling ~56%); meta‑analyses report pooled pCLE sensitivity ≈0.88 and specificity ≈0.79.

(chunks 99, 106)

Depth of invasion / lesion delineation (pCLE): Pilot data suggest pCLE may assist in assessing depth of invasion in colorectal lesions and delineating EMR margins with promising sensitivity/accuracy in small series, but require larger validation studies.

(chunk 81)

Studied clinical applications / evidence

Implied clinical indications studied (evidence summarized):

Pancreatic cysts/lesions (EUS‑nCLE adjunct): EUS‑guided nCLE has been studied as an adjunct to EUS‑FNA for classifying pancreatic cystic lesions with pooled diagnostic accuracy around 83% and measurable AE rates; studies suggest nCLE may improve classification versus CEA/EUS alone.

(chunks 85, 90, 86)

Indeterminate biliary strictures: pCLE during ERCP has been evaluated in multicenter prospective studies and meta‑analyses showing higher sensitivity than tissue sampling alone for detection of cholangiocarcinoma and improved real‑time diagnostic accuracy.

(chunks 99, 106)

Colorectal polyp histology prediction (ESS, digital chromoendoscopy): Elastic‑scattering spectroscopy and digital chromoendoscopy have been prospectively studied for real‑time polyp histology prediction; pilot and prospective ML‑augmented studies report high sensitivity/specificity and the potential to meet PIVI thresholds for diminutive polyps in high‑confidence scenarios.

(chunks 93, 96, 54)

Tumor visualization and staging in lung and head/neck: nCLE/pCLE feasibility studies in lung and head‑and‑neck cancers demonstrate high accuracy in small series for real‑time detection and staging, suggesting potential roles pending further validation.

(chunks 129, 131, 126)

Evidence summaries (no explicit coverage criteria in these chunks)

General evidence characteristics: Available studies across indications are frequently feasibility/pilot studies, single‑center series, or small multicenter trials reporting concordance with histology, sensitivity/specificity/accuracy estimates, and inter‑observer agreement metrics; authors consistently call for larger prospective in‑vivo validation trials before broad clinical adoption.

(chunks 126, 129, 131, 137)

Referenced evidence (no explicit policy criteria in extracted chunks)

Evidence base and clinical contexts addressed in references (no explicit coverage decision text present in these chunks).

Types of evidence cited: The referenced literature includes randomized controlled trials, prospective multicenter studies, systematic reviews, meta‑analyses, pilot feasibility studies, and device/regulatory summaries addressing optical in‑vivo imaging for detection, characterization, staging, and intra‑operative assessment of GI and urothelial lesions.

(chunks 144‑160)

Aetna explicitly identifies a broad set of in‑vivo optical analysis technologies and clinical indications as experimental and investigational because evidence of effectiveness is insufficient. Examples listed include in‑vivo analysis of colorectal polyps using chromoendoscopy, confocal laser endomicroscopy (including Cellvizio probe‑based systems), endocytoscopy, the EVIS EXERA 160A System, elastic‑scattering spectroscopy and other optical biopsy systems, narrow‑band and multi‑band imaging, and a range of specific clinical uses (for example, differentiation of colorectal polyps, evaluation of biliary strictures and pancreatic lesions, diagnosis and grading of bladder cancer, head and neck squamous cell carcinoma, lung and prostate lesions, evaluation of early gastric cancer, and assessment of epithelial barrier function).

High‑definition chromocolonoscopy showed only a marginal increase in adenoma detection versus high‑definition white‑light colonoscopy in a randomized trial, with no significant difference in detection of advanced neoplasms. Based on these findings the authors concluded that the data do not support routine use of high‑definition chromocolonoscopy for average‑risk colorectal cancer screening due to limited incremental benefit.

Narrow‑band imaging (NBI) has not demonstrated consistent benefit over white‑light endoscopy or chromoendoscopy for dysplasia surveillance in inflammatory bowel disease. Guideline reviews and comparative studies cited in the evidence base note that NBI detected fewer lesions than chromoendoscopy in some series and that advanced imaging modalities are not recommended for routine Barrett’s esophagus surveillance; therefore NBI is not recommended for routine IBD surveillance based on current evidence.

Multiple advanced optical modalities (including probe‑ and endoscope‑based confocal laser endomicroscopy, optical coherence tomography, autofluorescence imaging and upper‑tract NBI) have shown promise in specialized studies but the evidence is heterogeneous, often limited to small or single‑center series, and lacks validation for routine clinical implementation. Consequently the policy concludes that routine clinical implementation of many optical modalities is not supported by current evidence and such uses remain investigational.

Prospective evaluations of probe‑based CLE (pCLE) for real‑time differentiation of colorectal polyps report modest real‑world accuracy, low negative predictive value for small polyps, and substantial technical challenges in obtaining high‑quality images. The policy therefore states that routine use of pCLE to distinguish colorectal polyp histology or to replace standard biopsy-based histopathology is not supported given low NPV in routine settings, image‑quality and learning‑curve limitations, and limited added value compared with contemporary high‑definition endoscopy and digital chromoendoscopy.

Although confocal endomicroscopy has been used as an adjunct during ERCP to evaluate indeterminate biliary strictures, the document notes that available data are insufficient to demonstrate that confocal endomicroscopy combined with ERCP produces improved health outcomes. Therefore evidence is currently insufficient to establish clinical benefit for confocal endomicroscopy with ERCP for routine practice.

Probe‑based confocal laser endomicroscopy has a limited optical penetration depth (approximately 55–65 μm), which restricts imaging to superficial mucosal layers. Because of this shallow penetration, CLE cannot reliably assess deeper margins in muscle, submucosa or fascia; evaluation of deep invasion therefore remains limited when using CLE alone.

National guideline sources and recent reviews cited in the policy do not include CLE as a standard management technique for several tumor types. In particular, the referenced NCCN guideline compilations for head and neck cancers and for non‑small cell lung cancer do not mention confocal laser endomicroscopy as an accepted management tool in the cited guideline versions. This absence supports the view that CLE is not yet established as a standard guideline‑recommended technique for these indications.

This Clinical Policy Bulletin provides a partial description of benefits and evidence‑based coverage considerations; it does not constitute a contract or a complete statement of plan benefits. Specific plan exclusions, program provisions and benefit documents determine coverage for individual members, and those plan terms prevail over the bulletin when differences occur.

The policy bulletin is informational and not a guarantee of coverage or medical advice. Participating providers are independent practitioners responsible for medical decisions; providers must consult applicable plan documents and member benefits to determine coverage and should not rely on the bulletin alone to establish benefit entitlement.

Procedures and indications designated in the policy as experimental and investigational are described as not medically necessary for routine clinical care because the available evidence does not establish their effectiveness. Claims for services meeting those experimental/investigational descriptions may therefore be denied as not medically necessary.

Overall, the evidence summarized in the policy indicates insufficient proof that confocal endomicroscopy and related in‑vivo optical biopsy techniques produce improved health outcomes or are generalizable across routine practice settings. For this reason these technologies are not established as standard of care and are considered investigational for many listed indications until validated by larger, prospective, and practice‑representative studies.

The policy emphasizes that advanced imaging techniques have not demonstrated adequate, reproducible diagnostic accuracy in community practice to justify replacing standard biopsy‑based surveillance or obviating histopathologic assessment. Therefore routine use of advanced optical imaging to substitute for histopathology is not supported outside of validated protocols or research settings.

Technologies or indications lacking adequate evidence of diagnostic accuracy, clinical utility, or outcome benefit for the intended use are characterized as investigational. The policy therefore treats such technologies as not established for routine coverage until sufficient, high‑quality evidence demonstrates diagnostic performance and impact on clinical outcomes.

Given limited evidence, cost‑effectiveness concerns, image‑quality and operational challenges, and the need for validated training and standardized interpretation, the policy states that CLE should not replace standard biopsies at this time. Providers considering CLE must document indications, imaging findings and correlation with histopathology where performed; CLE remains an adjunctive and investigational tool rather than a biopsy substitute.

For ERCP‑related uses the policy notes that the current literature does not establish that confocal endomicroscopy improves patient‑centered outcomes compared with standard ERCP sampling techniques. As a result, the use of confocal endomicroscopy with ERCP for indeterminate biliary strictures is considered investigational pending further outcome‑focused validation.

Early head and neck applications of CLE (including intra‑operative margin assessment and diagnosis of laryngeal/pharyngeal carcinoma) have shown feasibility in small pilot series, but the evidence is preliminary. The policy therefore considers CLE for many head and neck indications to be experimental/investigational until larger in‑vivo validation studies confirm diagnostic reliability and clinical impact.

In a prospective study comparing probe‑based CLE and mucosal integrity testing for epithelial barrier assessment, pCLE did not differentiate GERD from non‑GERD nor correlate with in‑vitro permeability measures, whereas mucosal integrity testing correlated with in‑vitro permeability and performed better diagnostically. These results indicate that pCLE is not supported for evaluating epithelial barrier function or diagnosing GERD based on the evidence segment cited.

The document does not include explicit 'not medically necessary' coverage statements in every evidence paragraph; rather, it provides an evidence‑based classification that many applications are experimental/investigational and therefore not established as medically necessary for routine care. Payers and providers should refer to plan‑specific benefit documents for formal coverage decisions.

Regulatory device identifier citedFDA

P990050

FDA PMA Optical Biopsy System (PMA No. P990050)

Document rationale and supporting evidence if proposing to substitute optical diagnosis for tissue sampling.

Prior Authorization

Prior authorization recommended for nCLE

Needle-based confocal laser endomicroscopy (nCLE) for evaluation of indeterminate pancreatic cystic lesions may require prior authorization in many plans. Prior authorization is recommended particularly for larger cysts or lesions with concerning surgical features.

nCLE has shown promising diagnostic accuracy but carries procedure-related risks (e.g., pancreatitis); check plan rules for prior authorization and documentation requirements.
Document indication, prior imaging/CEA/cytology results, and patient consent addressing pancreatitis risk.

Prior Authorization

Prior authorization advisable for CLE/pCLE procedures

Confocal laser endomicroscopy (CLE) and probe‑based CLE (pCLE) are novel, often costly procedures with variable evidence across indications. Consider requiring prior authorization for CLE/pCLE to ensure appropriate use and documentation.

Confirm whether CLE/pCLE is considered investigational for the requested indication under the member’s plan.
Require documentation of prior noninvasive testing, expected impact on management, and clinician experience with the technique.

Note

Prior authorization not specified in this section

Some parts of this policy excerpt do not specify explicit prior authorization requirements. Where prior authorization is not specified, providers should still confirm coverage and any administrative requirements through plan resources.

Absence of a stated prior authorization mandate in this document does not guarantee coverage — always check plan systems or bulletins.
If no prior authorization is listed, submit complete documentation to support medical necessity at time of claim.

Prior Authorization

Prior authorization — check plan bulletin

Prior authorization requirements and administrative controls may vary by benefit plan and are described in the plan’s Clinical Policy Bulletin or member benefit documents. Providers must check the applicable bulletin or plan portal for the most current rules.

Refer to the plan-specific Clinical Policy Bulletin Notes and review history for updates.
When in doubt, contact plan provider services or use electronic prior authorization tools.

Denial Risk

Experimental/Investigational — Denial risk

Procedures and indications listed in this policy as "experimental and investigational" are subject to noncoverage and denial. Submissions for these services should include robust documentation; even with documentation, denials are possible.

Examples listed as investigational include CLE for many GI/urothelial indications, optical biopsy systems, and ERCP with optical endomicroscopy.
If submitting for an investigational indication, include research protocols or justification for medical necessity and request prior authorization or peer‑to‑peer review when available.

Note

Not stated in this excerpt

For some statements in the source evidence summaries, no definitive administrative action is stated. Providers should recognize where the policy or excerpt explicitly notes that an administrative requirement is "not stated" or "not specified" and seek clarification through plan channels.

Document that the excerpt did not specify plan action when querying coverage to avoid assumptions.
Use plan contact points to request clarification if needed.

Denial Risk

Risk of relying on optical diagnosis in routine practice

Relying on optical in‑vivo diagnosis alone in routine community practice carries risk because accuracy reported in specialized centers may not be reproducible. Incorrect management decisions (e.g., leaving neoplastic polyps in place) can result if in‑vivo optical diagnosis is used without adequate validation, training, and documentation.

When relying on optical diagnosis to guide management (e.g., resect-and-discard or diagnose-and-leave), document clinician training, confidence level, and the evidence basis supporting the decision.
Consider pathology confirmation if community-practice accuracy is uncertain or if management would change substantially.

Denial Risk

Insufficient evidence may lead to denial

The policy cites that existing evidence for many optical techniques is insufficient to establish effectiveness for routine clinical use; insufficient evidence may lead to denial when procedures are submitted as primary justification for management decisions.

Provide comprehensive supporting evidence when requesting coverage for novel optical procedures.
Consider prior authorization or peer review to reduce risk of claim denial.

Note

Not explicitly stated in this section

Some background study summaries and sections do not include explicit administrative instructions. Where the policy text is silent on administrative actions, providers should treat those sections as clinical evidence summaries and follow plan processes for coverage determination.

When the policy states "not explicitly stated," do not infer authorization — check plan systems.
Include study-comparison elements (e.g., CLE vs histopathology) in clinical notes to support claims where applicable.

Note

Administrative disclaimer and provider responsibility

This section contains background evidence summaries and is not itself an administrative instruction. Providers must follow plan benefit documentation and administrative rules when submitting claims or prior authorization requests.

Use the Clinical Policy Bulletin Notes and plan portals for operational requirements.
Treat the bulletin as guidance; the member contract governs coverage.

Documentation Required

Documentation of high‑confidence optical diagnosis vs histopathology

When high‑confidence in‑vivo optical predictions (e.g., NBI, i‑scan OE) are used to guide management, documentation should explicitly record the confidence level, imaging criteria met, and correlation plan with histopathology or surveillance recommendations.

Record whether the prediction was high‑confidence or low‑confidence and which validated criteria/classification system was used.
Document recommended surveillance interval or decision to leave/resect a lesion and the rationale tied to imaging findings.

Documentation Required

Document prediction confidence and surveillance recommendation

Clinical documentation must include the in‑vivo prediction confidence and the surveillance or management recommendation made based on that prediction, and should note whether histopathology was obtained or intentionally deferred.

If histopathology is deferred, document justification, clinician training, and plan for follow‑up or quality assurance.
Include correspondence with the patient about risks/benefits when management deviates from standard biopsy.

Documentation Required

When used, documentation should include correlation with histopathology and imaging findings

When CLE or related optical modalities are used, documentation should include the specific findings, how those findings correlate with histopathology or cytology when available, and whether the imaging materially changed patient management.

Capture operative/imaging findings, image counts, and paired histopathology locations when available.
Include summary of how CLE findings influenced clinical decisions (e.g., altered surgical margins, avoided biopsy).

Documentation Required

Document indication, imaging findings, correlation with prior imaging/CEA/cytology, and informed consent

For procedures such as nCLE, document the indication, lesion characteristics, imaging findings, prior relevant testing (CEA, cytology, imaging), informed consent (including risk of pancreatitis), and comparison with reference standards.

Record size and imaging appearance of pancreatic cystic lesions, prior EUS/CT findings, and CEA/cytology results.
Document patient counseling about pancreatitis risk and post‑procedure monitoring plan.

Note

Studies compared CLE-based diagnoses to standard histopathology/cytology

Studies of CLE often compared CLE-based diagnoses to standard histopathology or cytology and reported agreement metrics. When billing or requesting prior authorization for CLE, include study-comparison methods and relevant outcome measures if applicable to clinical decision-making.

Where available, append or reference paired histology comparisons, sensitivity/specificity, and study identifiers to support clinical justification.
Note whether local results mirror published performance.

Documentation Required

Image‑histology pairing and blinded classification documented in studies

Clinical studies frequently documented image-to-histology pairing and used blinded classification or independent reviewers. When CLE is used, include these methodological elements in documentation when possible to strengthen the evidentiary record.

Record number of images, methods of pairing images to biopsy sites, and whether blinded review or independent raters were used.
Include inter- and intra-observer agreement statistics when available.

Documentation Required

Study documentation elements to include when applicable

Research studies using CLE reported specific documentation elements such as number of images, concordance with histopathology/cytopathology, blinded rater methods, and diagnostic accuracy metrics. Incorporate these elements into clinical records when applicable.

Document number of CLE sequences/images acquired and evaluable rate.
Include concordance metrics and any validated scoring systems applied (e.g., Miami, Paris, DOC score).

Note

Provider responsibility — follow plan documentation and bulletin

Providers are responsible for following plan benefit documentation requirements and the Clinical Policy Bulletin. Treat the bulletin as a guide; ultimate coverage determinations are subject to the member contract and plan administrative processes.

Ensure clinical documentation supports the requested service and aligns with plan procedures for prior authorization and appeals.
Contact plan provider services for operational questions.

Note

Implementation caution for chromoendoscopy

Implementation of chromoendoscopy in some real‑world settings did not improve dysplasia detection versus white‑light endoscopy with targeted and random biopsies in important studies. Exercise caution before changing surveillance protocols or abandoning standard tissue sampling based solely on chromoendoscopy.

If proposing chromoendoscopy-based changes to surveillance practice, include evidence and local performance data.
Do not replace standard random or targeted biopsies without validated local outcomes and plan approval.

Note

Step‑therapy and utilization limits not specified

This section does not specify step‑therapy protocols or quantity limits. No step‑therapy requirements are described in the policy excerpts provided; verify plan-specific utilization management policies if relevant.

If a plan imposes step therapy or staging for advanced optical procedures, that information will be in the plan bulletin or prior authorization guidance.
When absent, provide full clinical rationale and prior testing to support requests.

inv-79: Confocal endomicroscopy — definition and basic context

DefinitionConfocal endomicroscopy: endoscopic technique providing microscopic images of cellular morphology in vivo during endoscopy

Evidence baseSupported mainly by small non-randomized safety and feasibility studies; promising but insufficient evidence of effectiveness

Clinical roleProposed for early detection and real‑time characterization of colorectal and other GI neoplasia; tissue biopsy remains the gold standard

inv-80: Narrow-band imaging (NBI) — imaging technique using light filters to enhance mucosal/vascular detail

TechniqueNarrow‑band imaging (NBI): an imaging technique using specific light filters to enhance mucosal and vascular contrast during endoscopy

SystemsAvailable on some Olympus systems (e.g., Evis Exera CLV‑160A with optional NBI filter); lacks standardization across vendors

Diagnostic performanceMeta-analyses report high pooled sensitivity (~92%) and specificity (~86%) for differentiating neoplastic vs non‑neoplastic polyps when used by experienced endoscopists

inv-81: Confocal laser endomicroscopy (CLE) — probe-based and endoscope-based variants

DefinitionConfocal laser endomicroscopy (CLE): endoscopic imaging modality providing microscopic in‑vivo images of mucosal microstructure; enables real‑time 'optical biopsy'

VariantsProbe‑based CLE (pCLE) and endoscope‑based CLE (integrated systems) exist; probe‑based platforms are commonly used

Evidence summaryPooled studies report high sensitivity for certain indications (e.g., BE‑associated neoplasia) but specificity and clinical utility are variable and study heterogeneity is substantial

inv-82: Narrow-band imaging (NBI) — virtual/digital imaging technology definition (alternate chunk)

DefinitionVirtual/digital chromoendoscopy (including NBI): image‑enhancement technology that digitally alters light output to emphasize mucosal and vascular detail without topical dyes

PerformanceMeta-analyses show digital chromoendoscopy differentiates neoplastic from benign polyps with sensitivity ~92% and specificity ~84%

LimitationsAccuracy is operator‑dependent and often derived from experienced centers; generalizability to routine practice is limited

inv-83: Endocytoscopy (EC) — contact light microscopy integrated into endoscopy

DefinitionEndocytoscopy (EC): contact light microscopy integrated into endoscopy providing very high magnification (eg, ~1,400×) of the superficial mucosal layer for in‑vivo cellular imaging

Depth/contrastVisualizes very superficial mucosa (contrast to CLE which images deeper, up to ~250 μm); suitable for detailed surface cellular assessment

Reported accuracySystematic review reported high sensitivity and specificity for colon polyps (eg, ~91% sensitivity and 100% specificity in cited reports), though studies are limited

inv-84: High-confidence prediction — definition and study relevance

DefinitionHigh‑confidence prediction: an in‑vivo optical diagnosis the endoscopist deems made with high certainty (eg, 'high‑confidence' NBI predictions)

Study relevanceHigh‑confidence stratification in studies yielded higher accuracy and in some cases met ASGE thresholds (eg, Repici et al showed ~90% sensitivity and >90% NPV for diminutive recto‑sigmoid polyps)

Documentation implicationWhen relying on optical diagnosis, studies recommend recording confidence level because high‑confidence predictions drove acceptable surveillance agreement

inv-85: Confocal laser endomicroscopy (CLE) — pooled study sensitivity context

Pooled sensitivityCLE pooled sensitivity for detection of Barrett’s‑associated neoplasia (per‑patient) reported at ~89% in pooled analyses

Specificity variabilitySpecificity estimates vary widely across studies (eg, pooled per‑patient specificity ~75% in some analyses; per‑location specificity higher), reflecting heterogeneity

Evidence caveatsMost studies are small, heterogeneous, and from specialized centers; further prospective trials are needed to determine clinical‑outcome benefit

inv-86: Confocal laser endomicroscopy (CLE) — probe-based optical imaging technique description

Technique descriptionProbe‑based CLE (pCLE) is a probe‑based optical imaging technique providing real‑time microscopic (in‑vivo histologic) images during endoscopy to assess mucosal microstructure

ApplicationsUsed to assess mucosal microarchitecture for diagnosis, margin assessment, and real‑time decision making in GI and urothelial lesions; often paired with histopathology in studies

LimitationsField of view is limited and technique requires identification of suspicious lesion prior to probe assessment; evidence remains preliminary for routine practice

inv-87: Digital chromoendoscopy / NBI — image-enhancement technologies definition

DefinitionDigital chromoendoscopy / NBI: image‑enhancement technologies that emphasize mucosal structures and vascular patterns to help differentiate neoplastic from benign lesions in real time

Constituent technologiesIncludes narrow‑band imaging, Fuji intelligent chromo endoscopy, iScan and other virtual/digital chromoendoscopy platforms

Meta‑analysis findingsPooled analyses show high sensitivity and specificity for neoplasia detection (digital chromoendoscopy sensitivity ~92.2%, specificity ~84.0%)

inv-88: pCLE description — probe-based CLE used during luminal endoscopy and nCLE via EUS-FNA needle

pCLE (probe‑based) and nCLE (needle‑based)pCLE: probe‑based CLE used during luminal endoscopy; nCLE: AQ‑Flex mini‑probe passed via an EUS‑FNA needle for intralesional/pancreatic cyst wall imaging

Clinical contextspCLE evaluated for biliary strictures (ERCP/POCS), luminal lesion grading, and margin assessment; nCLE evaluated primarily for pancreatic cystic lesion characterization

Evidence highlightsProspective studies report high sensitivity for pCLE in biliary strictures (eg, pCLE+ERCP sensitivity 89%) and high diagnostic performance for nCLE in PCLs (eg, Napoleon: conclusive rate 91%; Krishna: sensitivity 98% for mucinous PCLs) but AE risks (eg, pancreatitis) are noted

inv-89: nCLE — needle-based confocal laser endomicroscopy definition for pancreatic lesions

DefinitionnCLE (needle‑based CLE): AQ‑Flex mini‑probe passed through an EUS‑FNA needle into a pancreatic lesion to enable sub‑surface in‑vivo tissue analysis

Diagnostic performanceSystematic reviews/meta‑analyses report pooled diagnostic accuracy ~83% for EUS‑nCLE; individual studies report very high sensitivity/specificity for specific cyst types

Adverse eventsProcedure‑related AEs include post‑procedure pancreatitis (pooled AE rates ~2.3% for pancreatitis; overall AE rates up to ~5.4% reported), warranting informed consent and specialist expertise

inv-90: ESS — elastic-scattering spectroscopy definition

DefinitionElastic‑scattering spectroscopy (ESS): fiberoptic probe‑based spectral measurement of tissue scattering and absorption integrated into biopsy tools to predict polyp histology in real time

Pilot performancePilot studies report high accuracy (eg, Rodriguez‑Diaz 2015: sensitivity 91.5%, specificity 92.2%, accuracy 91.9% across 218 polyps) and prospective ML‑model validation with sensitivity ~0.92 and specificity ~0.87 in 367 polyps

Potential roleLow‑cost, real‑time classification platform that may meet PIVI thresholds for diminutive polyps pending further validation

inv-91: pCLE — probe-based confocal laser endomicroscopy (brief definition)

DefinitionpCLE (probe‑based confocal laser endomicroscopy): real‑time in‑vivo optical biopsy using a probe to visualize mucosal microstructure during endoscopy (magnification up to ~1,000×)

UsesEvaluated for colorectal polyp characterization, Barrett’s esophagus, biliary strictures (with ERCP/POCS), bladder tumor grading and margin assessment in surgical settings

LimitationsRequires lesion localization prior to probe use; limited field of view and image penetration depth; evidence largely from specialized centers and small studies

inv-92: CLE penetration depth — approximately 55–65 micrometers

Penetration depthCLE probe penetration depth approximately 55–65 micrometers, limiting assessment of deeper submucosal, muscular, or fascial margins

Clinical implicationUnable to reliably evaluate deep margin invasion (eg, muscle/fascia) or fully distinguish carcinoma‑in‑situ from invasive disease in some anatomic sites

RecommendationCLE findings should be corroborated with histopathology for assessment of deeper invasion and surgical planning

inv-93: pCLE under POCS — definition for biliary stricture evaluation

DefinitionpCLE under POCS: probe‑based confocal laser endomicroscopy performed under direct view of per‑oral cholangioscopy for biliary stricture evaluation

Reported accuracySingle‑center study reported pCLE under POCS sensitivity 94.1%, specificity 92.3%, accuracy 93.3% for biliary strictures

ContextPromising technique for biliary strictures but requires further validation in larger, multicenter studies

inv-94: nCLE / pCLE — modalities summary

SummarynCLE and pCLE: modalities that provide real‑time microscopic imaging at the needle tip (nCLE) or via an endoscopic probe (pCLE) to visualize cellular and microstructural features in vivo

Distinct usesnCLE primarily used with EUS‑FNA for pancreatic cysts and trans‑needle assessment; pCLE used during ERCP, POCS, and luminal endoscopy for mucosal evaluation

Evidence noteBoth modalities show high diagnostic performance in selected studies but overall evidence is heterogeneous and often from specialized centers; AE risks (eg, pancreatitis with nCLE) should be considered

inv-95: MIT (mucosal integrity testing) — definition and study context

DefinitionMucosal integrity testing (MIT): method to assess epithelial barrier function; in cited study MIT correlated with in‑vitro permeability and differentiated GERD from non‑GERD better than pCLE

Study findingIn prospective study, MIT discriminated GERD versus non‑GERD (sensitivity 76%, specificity 72%) and correlated with in‑vitro permeability; pCLE did not correlate

ImplicationMIT may be more promising than pCLE for assessing epithelial barrier function in GERD, but further validation required

inv-96: probe-based confocal laser endomicroscopy (pCLE) — definition (reference chunks)

DefinitionProbe‑based confocal laser endomicroscopy (pCLE): a real‑time, in‑vivo optical biopsy technique using probe‑based confocal microscopy to visualize mucosal microstructure during endoscopy

Magnification & depthProvides high magnification (up to ~1,000×) and depth of mucosal imaging; used in studies across GI and urothelial sites

Evidence contextMultiple validation and diagnostic accuracy studies cited; clinical utility remains under investigation and is not yet widely established in routine practice

inv-97: needle-based confocal laser endomicroscopy (nCLE) — definition (reference chunks)

DefinitionNeedle‑based confocal laser endomicroscopy (nCLE): confocal imaging performed through an EUS or other needle to evaluate cystic or solid lesions in‑vivo at the needle tip

ApplicationsUsed for pancreatic cystic lesion characterization, lung tumor/node assessment, and other trans‑needle assessments in feasibility studies

Evidence summarySystematic reviews report pooled diagnostic accuracy ~83% for pancreatic lesions; individual validation studies report high sensitivity/specificity for specific lesion types

inv-98: narrow-band imaging (NBI) — definition (reference chunks)

DefinitionNarrow‑band imaging (NBI): endoscopic optical enhancement technique using narrow bandwidth light to improve detection and characterization of mucosal lesions

Diagnostic performanceSystematic reviews and meta‑analyses report high pooled sensitivity (~92%) and specificity (~86%) for differentiating neoplastic from non‑neoplastic colon polyps when used by experienced endoscopists

Clinical limitationRCTs and meta‑analyses show NBI does not consistently improve adenoma detection over high‑definition white‑light colonoscopy; benefits often limited to experienced operators or specific comparisons

2023-10-17last_reviewLatest

Policy last reviewed and documented in the policy history.

Administrative metadata: this policy was last reviewed on 10/17/2023, has an effective date of 04/24/2009, and the next scheduled review is 08/22/2024. External resources, glossary links, and non‑English language support options are provided in the Additional Information section.

The policy includes links to external resources and notices and lists available non‑English language support options. It also contains legal and service disclaimers noting that the Clinical Policy Bulletin is a partial description of benefits, is not a contract, and that providers are responsible for clinical care decisions; members seeking language assistance are directed to contact the number on their member ID card.

Non‑English language supports are listed for multiple languages (including Español, 中文, Tiếng Việt, 한국어, Tagalog, Pусский, العربية and others) and the policy directs readers to Aetna’s language assistance resources for additional support.

The policy contains a legal and service disclaimer stating that Clinical Policy Bulletins are intended to assist in administering plan benefits, do not constitute a contract or guarantee coverage, and that participating providers are independent practitioners; the bulletin may be updated and is subject to change.